Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extracorporeal photopheresis to prevent graft-versus-host disease after allogeneic stem cell transplantation
2017-000614-39Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of methoxsalen in Acute Graft-Versus-Host Disease (aGvHD) and graft-versus-host disease (GVHD), sponsored by Oslo University Hospital. Primary endpoint: Fraction of graft-versus-host disease. Started Mar 2017; status: completed.
02
Drugs
methoxsalen
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2017-000614-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000614-39.